Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xenon Pharmaceuticals excels in epilepsy treatment with strong IP strategy

Xenon Pharmaceuticals demonstrated strong performance and promising efficacy data for XEN1101 in epilepsy treatment, supported by a robust IP strategy and CNS penetration.
While facing challenges in patient enrollment and rising expenses, the company is exploring new therapeutic areas and potential milestone payments through partnerships.
Opportunities lie in expanding XEN1101's market reach, establishing a leadership position in epilepsy treatment, and navigating uncertainties in pediatric indications and generic competition.

Xenon Pharmaceuticals advances epilepsy program amid financial stability and challenges

Xenon Pharmaceuticals showcased progress in their epilepsy program and financial stability, while addressing challenges in enrollment dynamics and competitive pressures.
The company's focus on managing R&D expenses and upcoming milestones reflects a strategic approach to advancing their clinical programs.
Opportunities in the epilepsy market and ongoing formulation development for pediatric patients position Xenon for potential growth and innovation.

Xenon Pharmaceuticals excels in trials and finances, eyes global expansion

Xenon Pharmaceuticals showcases strong performance in key trials and financial stability, supported by positive market reception and strategic leadership additions.
While facing challenges in trial completion and enrollment trends, the company has opportunities to expand market reach, innovate in treatment approaches, and explore global partnerships.
Overall, Xenon's focus on advancing novel therapies for neurological disorders positions it well for future growth and success in the competitive pharmaceutical landscape.

Xenon Pharmaceuticals advances epilepsy and MDD treatments, poised for growth

Xenon Pharmaceuticals showcased strong performance in advancing XEN1101 for epilepsy and MDD treatments, backed by extensive data and strategic partnerships.
While facing challenges in enrollment timelines and technical complexities, the company is well-positioned financially and strategically for future growth.
Opportunities abound in addressing unmet needs, expanding drug applications, and advancing new molecules into clinical development.
Overall, Xenon Pharmaceuticals' Q3 earnings call highlighted a promising outlook for drug development and market positioning.

Xenon Pharmaceuticals excels in Q4, poised for growth in epilepsy and MDD

Xenon Pharmaceuticals showcased strong financials, program advancements, and market insights in Q4 2023, positioning the company well for future growth.
The company's focus on safety, tolerability, and efficacy in MDD treatment, along with leveraging learnings across programs, demonstrates strategic foresight.
While facing challenges in R&D spend allocation and regulatory discussions, Xenon can capitalize on opportunities for operational efficiency and market expansion.
Investor interest in Xenon's pipeline and the potential of its programs in epilepsy and MDD highlight a promising trajectory for the company.

Xenon Pharmaceuticals reports strong Q1 performance and addresses market needs

Xenon Pharmaceuticals is well-positioned with a strong financial base and promising pipeline.
The company faces challenges in conducting well-powered MDD trials and addressing market needs.
Opportunities lie in the substantial unmet need in the major depressive market and azetukalner's potential benefits.
Strategic planning and FDA alignment support Xenon's progress in key therapeutic areas.

Xenon Pharmaceuticals excels in Q3, poised for groundbreaking treatments

Xenon Pharmaceuticals demonstrated strong financial performance and progress in developing azetukalner for epilepsy and major depressive disorder.
Confidence in the lead product's potential for groundbreaking treatments was evident, supported by ongoing outreach efforts and future milestones.
While facing challenges in addressing complex analyst inquiries and navigating regulatory requirements, Xenon Pharmaceuticals is well-positioned to capitalize on opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, November 8, 2022.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Corporate Update

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has announced that the US Food and Drug Administration (FDA) has requested additional information from the manufacturing partner for the company's xenon-129 gas blend drug. The company said this request is related to the recent cGMP (Current Good Manufacturing Practice) pre-approval inspection at the partner's production facility.

Polarean Imaging says US FDA requests additional information from manufacturing partner of its xenon-129 gas blend drug

BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells Fargo Securities Healthcare Conference taking place in Everett, MA from September 7-9, 2022.

Xenon Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Marc Goodman - SVB Andrew Tsai - Jefferies David Hoang - SMBC Lachlan Hanbury - William Blair Operator Good afternoon and welcome to the Xenon Pharmaceuticals Reports Second Quarter Results Conference Call. [Operator Instructions] Thank you.

Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q2 2022 Results - Earnings Call Transcript

Xenon remains on track to initiate the XEN1101 Phase 3 program within second half of this year

Xenon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BURNABY, British Columbia, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, August 9, 2022.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update

BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William Blair Biotech Focus Conference 2022 to be held July 12-13, 2022 in New York, NY.

Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022

BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters' option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. The common shares were offered at a public offering price of $30.50 per common share and the pre-funded warrants were offered at a price of $30.4999 per pre-funded warrant, with each pre-funded warrant having an exercise price of $0.0001. The aggregate gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were approximately $287.5 million.

Xenon Pharmaceuticals Announces Closing of $287.5 Million Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo.

Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

BURNABY, British Columbia, June 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 7,868,854 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 327,868 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $30.50 per common share and the pre-funded warrants are being offered at a price of $30.4999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $250.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,229,508 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 27, 2022, subject to customary closing conditions.

Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced an underwritten public offering of its common shares. Underwriters of the offering will be granted an option for a period of 30 days to purchase an additional 15% of common shares at the public offering price.

Xenon Pharmaceuticals Shares Drop On Proposed Public Offering

New XEN1101 Phase 2b X-TOLE sub-group analysis demonstrates statistically significant efficacy results at all doses at Week 1, differentiating XEN1101 with rapid onset to seizure reduction

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

XEN1101 Phase 3 program for the treatment of focal onset seizures to be initiated in the second half of 2022 and New Drug Application expected to be submitted after completion of first Phase 3 clinical trial (X-TOLE2) along with the completed Phase 2b (X-TOLE) clinical trial

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

BURNABY, British Columbia, June 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and present at the 2022 Jefferies Healthcare Conference to be held June 8-10, 2022 in New York, NY.

Xenon Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 7.89% and 4.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals (XENE) Reports Q1 Loss, Misses Revenue Estimates

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President & Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Yatin Suneja - Guggenheim David Hoang - SMBC Laura Chico - Wedbush Operator Good day. Thank you for standing by, and welcome to the Xenon Pharmaceuticals Reports First Quarter Results Call 2022.

Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q1 2022 Results - Earnings Call Transcript

XEN1101 “End of Phase 2” Meeting with FDA to take Place in Second Quarter and Initiation of Phase 3 in Adult Focal Epilepsy Expected in the Second Half of 2022

Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

BURNABY, British Columbia, May 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, May 10, 2022.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Corporate Update

BURNABY, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference.

Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the Stifel 2022 CNS Days (virtual) conference.

Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days

Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q4 2021 Results - Earnings Call Transcript

Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today

Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update

BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial results for the year ended December 31, 2021 and provide a corporate update after the close of U.S. financial markets on Tuesday, March 1, 2022.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update

BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.

Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Neurocrine Biosciences

Xenon Pharmaceuticals Inc's (NASDAQ: XENE) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX) achieved a regulatory milestone, triggering a payment of $15.0 million to Xenon.  The FDA accepted Neurocrine's protocol amendment that expands the study population to include subjects between 2 and 11 years in the ongoing Phase 2 study of NBI-921352 in pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).

News for Xenon Pharmaceuticals Stock (XENE)